ECSP088243A - Combinaciones que comprenden dmxaa para el tratamiento de cáncer - Google Patents

Combinaciones que comprenden dmxaa para el tratamiento de cáncer

Info

Publication number
ECSP088243A
ECSP088243A EC2008008243A ECSP088243A ECSP088243A EC SP088243 A ECSP088243 A EC SP088243A EC 2008008243 A EC2008008243 A EC 2008008243A EC SP088243 A ECSP088243 A EC SP088243A EC SP088243 A ECSP088243 A EC SP088243A
Authority
EC
Ecuador
Prior art keywords
combinations
dmxaa
cancer treatment
understanding
compounds
Prior art date
Application number
EC2008008243A
Other languages
English (en)
Inventor
Colin Green
Lloyd Kelland
Gail Rowlinson-Busza
Original Assignee
Antisoma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0517386A external-priority patent/GB0517386D0/en
Priority claimed from GB0604114A external-priority patent/GB0604114D0/en
Application filed by Antisoma Plc filed Critical Antisoma Plc
Publication of ECSP088243A publication Critical patent/ECSP088243A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a combinaciones de compuestos tales como compuestos de la clase de ácido xantenon-acético como ácido 5,6-dimetilxantenon-4-acético (DMXAA) y aglutinantes del factor de crecimiento endotelial vascular, en particular el anticuerpo monoclonal AvastinTM (bevacizumab). Más particularmente, la invención se refiere al uso de tales combinaciones en el tratamiento de cáncer y formulaciones farmacéuticas que contienen tales combinaciones.
EC2008008243A 2005-08-26 2008-03-05 Combinaciones que comprenden dmxaa para el tratamiento de cáncer ECSP088243A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0517386A GB0517386D0 (en) 2005-08-26 2005-08-26 Combinations for the treatment of cancer
GB0604114A GB0604114D0 (en) 2006-03-02 2006-03-02 Combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
ECSP088243A true ECSP088243A (es) 2008-08-29

Family

ID=37429252

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008243A ECSP088243A (es) 2005-08-26 2008-03-05 Combinaciones que comprenden dmxaa para el tratamiento de cáncer

Country Status (14)

Country Link
US (1) US20100297112A1 (es)
EP (1) EP1917011A1 (es)
JP (1) JP2009506019A (es)
KR (1) KR20080047402A (es)
AU (1) AU2006283371A1 (es)
BR (1) BRPI0614965A2 (es)
CA (1) CA2620436A1 (es)
EC (1) ECSP088243A (es)
IL (1) IL189376A0 (es)
MA (1) MA29786B1 (es)
NO (1) NO20080649L (es)
RU (1) RU2404764C2 (es)
TN (1) TNSN08056A1 (es)
WO (1) WO2007023302A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002009700A1 (en) 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
CN101896177A (zh) * 2007-12-13 2010-11-24 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
KR102216772B1 (ko) * 2018-05-18 2021-02-17 주식회사 종근당 혈관차단제 및 탁산 화합물을 포함하는 암 예방 또는 치료용 조성물
WO2025226040A1 (ko) * 2024-04-25 2025-10-30 (의) 삼성의료재단 종양 혈관 파괴용 약학 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655470A (en) * 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
FR2516922A1 (fr) * 1981-11-25 1983-05-27 Lipha Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
DE3587500T2 (de) * 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US4704355A (en) * 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
RU2196137C2 (ru) * 1996-08-08 2003-01-10 Зенека Лимитед Производные хиназолина и их применение в качестве ингибиторов фактора роста эндотелия сосудов
JP2001509143A (ja) * 1996-12-13 2001-07-10 イーライ・リリー・アンド・カンパニー 大脳病巣性卒中のためのロイコトリエンアンタゴニスト
US5910505A (en) * 1997-03-21 1999-06-08 Eli Lilly And Company Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
EP1033364B1 (en) * 1999-03-01 2005-02-23 Pfizer Products Inc. Cyano containing oxamic acids and derivatives as thyroid receptor ligands
EP1189611B1 (en) * 1999-06-14 2006-05-03 Cancer Research Technology Limited Cancer therapy
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
AU3822701A (en) * 2000-02-17 2001-08-27 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JP2001247459A (ja) * 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
WO2002009700A1 (en) * 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
CA2523260A1 (en) * 2003-04-21 2004-11-04 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations

Also Published As

Publication number Publication date
KR20080047402A (ko) 2008-05-28
TNSN08056A1 (en) 2009-07-14
EP1917011A1 (en) 2008-05-07
IL189376A0 (en) 2008-06-05
JP2009506019A (ja) 2009-02-12
RU2008111492A (ru) 2009-10-10
WO2007023302A1 (en) 2007-03-01
RU2404764C2 (ru) 2010-11-27
NO20080649L (no) 2008-05-26
BRPI0614965A2 (pt) 2016-09-13
AU2006283371A1 (en) 2007-03-01
CA2620436A1 (en) 2007-03-01
MA29786B1 (fr) 2008-09-01
US20100297112A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
ECSP099341A (es) Nuevos anticuerpos antiproliferativos
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
CY1121980T1 (el) Αντισωματα anti-cd26 και χρησεις εξ αυτων
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
CR9463A (es) Pirrolinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
AR047928A1 (es) Derivados de tetrahidropiridoindol
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
BRPI0710331A2 (pt) Compostos heteroarila monocíclicos para tratamento de câncer e composição
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
MX2017013321A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CR10555A (es) Vacunas para malaria
UY33643A (es) ?Conjugado cristalino de naloxol-PEG?.
AR057239A1 (es) Inmunoglobulinas
TNSN08056A1 (en) Combinations comprising dmxaa for the treatment of cancer
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
ECSP088242A (es) Combinaciones que comprenden dmxaa para el tratamiento de cancer
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia